Multiple Sclerosis Drugs Market to Gain US$ 32.7 billion Revenue with 3.5% CAGR by 2030 | Growth Plus Reports

Pune, Nov. 17, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Multiple Sclerosis Drugs Market will clock US$ 32.7 billion by 2030. The rapidly increasing adoption of digitalization due to growing urbanization is a major driver for the Multiple Sclerosis Drugs Market. This exclusive information is published by Growth Plus Reports in its report titled “Multiple Sclerosis Drugs Market – Global Outlook & Forecast 2022-2030

Download Sample PDF Brochure of Multiple Sclerosis Drugs Market:

https://growthplusreports.com/inquiry/request-sample/multiple-sclerosis-drugs-market/7983

Growth Drivers

The rising cases of multiple sclerosis globally, the rising aging population, new drug launches by key players, and increased drug approvals are the factors that are responsible for the growth of the global multiple sclerosis drugs market.

The global multiple sclerosis drugs market has been analyzed from four perspectives: drug class, route of administration, distribution channel, and region.

Excerpts from ‘By Drug Class Segmentation’

Based on drug class, the global multiple sclerosis drugs market is subdivided into

• Immunosuppressants
• Immunomodulators
• Interferons
• Others

The immunosuppressant segment is projected to witness robust growth in the forecast period. This is due to the benefits of these medications, which are anticipated to drive growth over the forecast period. These benefits include high efficacy, efficient administration with low dosage requirements, and few side effects.

Excerpts from ‘By Route of Administration Segmentation’

Based on route of administration, the global multiple sclerosis drugs market is subdivided into

• Oral
• Injection

The injection segment is further divided into

• Intramuscular
• Intravenous
• Subcutaneous

Although, the injection segment holds most of the market share currently, it is suggested that the oral segment is likely to grow with a high CAGR in the forecast period. This is because of the new drug developments and increased demand.

Excerpts from ‘By Region Segmentation’

Based on region, the global multiple sclerosis drugs market has been segmented into

• North America
• Europe
• Asia Pacific
• The Rest Of The World

Asia Pacific region is expected to project a high CAGR during the forecast period. This is attributed to the penetration of new pharmaceuticals in the region with the objective to introduce innovative drugs for the treatment of multiple sclerosis. Since this neurodegenerative disease is an economic burden, governments are taking initiatives to spread awareness for the timely diagnosis and treatment of the disease. Hence, such factors are likely to boost the MS drugs market growth.

Excerpts from ‘Competitive Landscape’

The prominent players operating in the global multiple sclerosis drugs market are,

• F. Hoffmann-La Roche Ltd
• Celgene Corporation
• Biogen Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Acorda Therapeutics Inc.
• Novartis AG
• Actelion Pharmaceuticals
• AstraZeneca plc
• AbbVie Inc.
• Mylan N.V.
• GlaxoSmithKline plc

Inquire Before Buying This Research Report:

https://growthplusreports.com/inquiry/before-buying/multiple-sclerosis-drugs-market/7983

Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS  
   1. Immunosuppressants
   2. Immunomodulators
   3. Interferons
   4. Others
6. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION 
   1. Oral 
   2. Injection
      1. Intramuscular
      2. Intravenous
      3.  Subcutaneous
7. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
   1. Online Pharmacy
   2. Retail Pharmacy
   3. Hospital Pharmacy

TOC Continue…

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pipeline Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Quickly Purchase Premium Copy of Multiple Sclerosis Drugs Market Report:

https://growthplusreports.com/checkout?_token=ZbtgYNsAcb0Wj1HSq0HBLIyKIvslsdIqgl5J1QhC&report_id=7983&license=Single

About Us        

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

 Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

            Manan Sethi
Director, Market Insights
Email: enquire@growthplusreports.com
Phone no: +91 96545 76783
Web: https://growthplusreports.com/